The companies are sharing the cost of the trial, but no other money is changing hands.
Note that ABI-H0731 is not ASMB’s latest-generation core inhibitor (CpAM), and it has shown only modest efficacy as monotherapy—see #msg-156515976 and #msg-152253534.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.